Accessibility Menu
Sight Sciences logo

Sight Sciences(NASDAQ) SGHT

Market Cap$448.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-76%
5 Year-78%
1 Year+100%
1 Month+66%
Premium Feature
Moneyball Superscore
52/100
$8.28
+1.60%
+0.13Today
After hours$8.25-$0.03 (-0.36%)
Sight Sciences last closing stock price
MetricPriceDate
Last closeUSD 8.152026-08-20
Sight Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.04%USD 8.322026-08-13
1 month+65.99%USD 4.912026-07-21
3 month+62.03%USD 5.032026-05-22
Year to date+2.77%USD 7.932025-12-31
1 year+100.25%USD 4.072025-08-20
3 year+13.67%USD 7.172023-08-21
5 year-78.23%USD 37.442021-08-20
Since inception-75.67%USD 33.502021-07-15

Sight Sciences Financials at a Glance

Market Cap

$448.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$83.38M

Net Income (TTM)

-$29.76M

EPS (TTM)

-$0.56

P/E Ratio

-14.64

Dividend

$0.00

Beta (Volatility)

1.87 (High)

Price

$8.28

Volume

180,590

Open

$8.25

Previous Close

$8.26

Daily Range

$8.05 - $8.35

52-Week Range

$3.19 - $9.24

Estimated Earnings Date

Nov 5, 2026

SGHT News

GettyImages-1273470469

Here's What Investors Need to Know About Sight Sciences Stock

Rachel WarrenJan 12, 2022
GettyImages-1279371084

Should Investors Consider Sight Sciences Stock?

Rachel WarrenJan 10, 2022

SGHT: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sight Sciences

Sight Sciences, Inc. makes tools that help doctors save sight. Its devices treat high eye pressure and severe dry eye disease. These products help people avoid going blind from common eye issues.

Tools for Healthier Eyes

  • Interventional Glaucoma: Tools like OMNI and SION used to lower eye pressure; represented 88.6% of revenue in the second quarter of 2026.
  • Interventional Dry Eye: Wearable eyelid technology for treating blocked oil glands; accounted for 11.4% of revenue in the second quarter of 2026.
  • OMNI Surgical System: Handheld device used to reduce fluid pressure in the eyes of adults with glaucoma.
  • TearCare System: Wearable devices that use heat and manual pressure to clear blocked oil glands in the eyelids.

Expanding the Reach

  • Established direct commercial operations in the United Kingdom and Germany to sell surgical products.
  • Reduced its workforce and operating costs during the third quarter of 2025 to improve efficiency.
  • Entered a loan agreement in Jan. 2024 to provide up to $65.0 million in credit.
  • Updated fee schedules for the TearCare procedure in late 2025 to increase patient access and insurance coverage.

How the Business Operates

Sight Sciences uses a direct sales force to train eye care professionals on new treatments. It also uses third-party suppliers to manufacture its medical device components.

Sight Sciences by the Numbers

  • Total revenue was $23.4 million for the three months ended June 30, 2026, up 19.6% year over year.
  • Gross margin was 91.4% for the quarter ended June 30, 2026, up from 84.8% in the same period last year.
  • Net loss was $17.4 million for the six months ended June 30, 2026, down 33.2% year over year.
  • Cash and cash equivalents reached $79.8 million as of June 30, 2026.

The Bottom Line

Sight Sciences has moved from developing new technologies to commercializing devices for glaucoma and dry eye disease. The company focus has shifted toward building insurance coverage and reducing operating costs to reach long-term profitability.

AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

186

CEO

Paul Badawi, MBA

Website

www.sightsciences.com

Headquarters

Menlo Park, CA 94025, US

SGHT Financials

Key Financial Metrics (TTM)

Gross Margin

87.96%

Operating Margin

-33.43%

Net Income Margin

-35.69%

Return on Equity

-50.64%

Return on Capital

-35.43%

Return on Assets

-28.37%

Earnings Yield

-6.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$448.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

55.09M

Volume

180.59K

Avg. Volume

221.56K

Financials (TTM)

Gross Profit

$73.34M

Operating Income

-$27.88M

EBITDA

-$25.75M

Operating Cash Flow

-$23.24M

Capital Expenditure

-$93.00K

Free Cash Flow

-$23.33M

Cash & ST Invst.

$79.75M

Total Debt

$41.97M

Sight Sciences Performance Analysis

Sight Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 71,331,00045.7%
20232023-12-31USD 81,056,00013.6%
20242024-12-31USD 79,866,000-1.5%
20252025-12-31USD 77,363,000-3.1%
Sight Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.7%
Q42025-12-312.4%
Q12026-03-31-3.4%
Q22026-06-3018.7%
Sight Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.8036.0%
20232023-12-31USD -1.14-36.6%
20242024-12-31USD -1.03-10.1%
20252025-12-31USD -0.74-28.3%
Sight Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3030.4%
Q42025-12-3151.0%
Q12026-03-31-206.1%
Q22026-06-3066.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$23.39M

+19.5%

Gross Profit

$21.37M

+28.9%

Gross Margin

91.39%

N/A

Market Cap

$448.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.41M

N/A

Employees

186

N/A

Net Income

-$4.45M

+62.8%

EBITDA

-$4.55M

+56.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$79.75M

-21.4%

Total Debt

$41.97M

+3.5%

Accounts Receivable

$11.39M

+18.4%

Inventory

$5.70M

-8.4%

Long Term Debt

$31.45M

-21.4%

Short Term Debt

$10.53M

+1759.5%

Return on Assets

-28.37%

N/A

Return on Invested Capital

-33.04%

N/A

Free Cash Flow

-$5.68M

+26.7%

Operating Cash Flow

-$5.66M

+24.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MASS908 Devices Inc.
$10.68+3.19%
SENSSenseonics Holdings, Inc.
$9.71+10.09%
VMDViemed Healthcare, Inc.
$8.85+3.27%
CERSCerus Corporation
$2.81+0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About SGHT

What is the current price of Sight Sciences?

Sight Sciences is trading at $8.26 per share.

What is the 52-week range for Sight Sciences?

Over the past 52 weeks, Sight Sciences has traded between $3.19 and $9.24.

How much debt does Sight Sciences have?

As of the most recent reporting period, Sight Sciences reported total debt of $41.97M.

How much cash does Sight Sciences have on hand?

Sight Sciences reported $79.75M in cash and cash equivalents in its most recent financial results.

What is Sight Sciences’s dividend yield?

Sight Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services